Every 424B that REVIVA PHARMA HLDGS INC (RVPH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow RVPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RVPH filings page.
Reviva Pharmaceuticals Holdings, Inc. is offering 6,283,334 shares of common stock together with Series G and Series H common warrants and up to 383,333 Pre-Funded Warrants in a primary, best-efforts offering described in this prospectus supplement.
The combined public offering price is $1.50 per share and accompanying Series G and H Common Warrants; Series G warrants expire five years and Series H warrants expire 12 months after issuance. Pre-Funded Warrants carry a $0.0001 exercise price and may be used to avoid exceeding 4.99% (or, at purchaser election, 9.99%) beneficial ownership limits. The offering may terminate on April 13, 2026 and is expected to settle in a single closing; proceeds to the issuer are described as net of Placement Agent fees.
The prospectus supplement gives effect to a one-for-twenty reverse stock split effective March 9, 2026. Shares outstanding used to calculate post-offering figures are 6,443,710 as of March 17, 2026.
Reviva Pharmaceuticals Holdings, Inc. is offering shares of common stock together with Series G and Series H common warrants and pre-funded warrants in a public offering described in this preliminary prospectus supplement, subject to completion.
The offering is structured as bundled common stock (or pre-funded warrants) sold together with one Series G Common Warrant and one Series H Common Warrant per unit, with Series G exercisable for five years and Series H exercisable for 12 months. The company effected a one-for-twenty reverse stock split effective March 9, 2026. Shares outstanding were 6,443,710 as of March 16, 2026 (post-split). The offering is a best-efforts, no-minimum offering to be conducted at a fixed public offering price and expected to settle in a single closing. Use of proceeds is stated as funding R&D, including the planned RECOVER-2 Phase 3 trial for brilaroxazine, and for working capital and general corporate purposes.